WO2003016914A1 - Kit de diagnostic simultane d'une pluralite de maladies infectieuses et technique de preparation de celui-ci - Google Patents
Kit de diagnostic simultane d'une pluralite de maladies infectieuses et technique de preparation de celui-ci Download PDFInfo
- Publication number
- WO2003016914A1 WO2003016914A1 PCT/CN2001/001519 CN0101519W WO03016914A1 WO 2003016914 A1 WO2003016914 A1 WO 2003016914A1 CN 0101519 W CN0101519 W CN 0101519W WO 03016914 A1 WO03016914 A1 WO 03016914A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antigen
- solution
- colloidal gold
- minutes
- room temperature
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
- G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/571—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses for venereal disease, e.g. syphilis, gonorrhoea
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
- G01N33/5761—Hepatitis B
Definitions
- the present invention relates to the field of biotechnology, and in particular, to a kit for simultaneously detecting multiple infectious diseases and a preparation method thereof. Background technique
- Hepatitis B, Hepatitis C, Syphilis and AIDS are four common infectious diseases. According to the statistical annual report of the Ministry of Health in 2000, the incidence of these four diseases accounted for about 27.57% of the total number of infectious diseases, which caused great harm to society and people's lives.
- Hepatitis B is inflammation that can be caused by drugs, toxins, and viruses.
- HBV hepatitis B virus
- blood transfusions plasma, blood products, or the use of virus-contaminated syringe needles, acupuncture needles, blood collection devices, and hemodialysis.
- virus-contaminated syringe needles acupuncture needles
- blood collection devices and hemodialysis.
- infection through blood transfusion has attracted great attention because of its high incidence, short onset time, and wide affected population.
- hepatitis C infection is mainly acute clinical patients and asymptomatic subclinical patients, chronic patients and virus carriers.
- the blood of patients is infectious 12 days before the onset of illness, and can be poisoned for more than 12 years.
- Hepatitis C infection is mainly caused by blood transfusion.
- hepatitis C is the most common type of hepatitis infected after blood transfusion.
- 30-90% of hepatitis infected after blood transfusion abroad is hepatitis C.
- Hepatitis C accounts for 1/3 of hepatitis infected with blood transfusion.
- Syphilis patients are the only source of infection for Treponema pallidum. Sexual contact infections account for 95%.
- the donor if the donor is a syphilis patient, it can be transmitted to the recipient. Blood donors can spread syphilis if they have syphilis and are at the stage of treponema pyloriemia.
- Treponema pallidum has low viability in vitro, survives for 48-72 hours at ° C, has no infectivity at 40 ° C, and immediately dies at 100 ° C. STDs have increased in China in recent years. Therefore, it is necessary to attach great importance to the prevention of blood transfusion transmission.
- HIV virus is the pathogen of AIDS, and the general source of infection is blood, semen, Yin Mainly secretions, breast milk and so on. If it is transfused with HIV-infected blood, the probability of infection with HIV is estimated to be more than 90% (in contrast, the risk of one-time transmission is a few percent to less than 1%), and the amount of HIV introduced into a blood transfusion is very large. After infection by this method, it will soon develop into AIDS, with an average time of 3 to 5 years (approximately 2 years for children).
- This method requires 400 / ⁇ 1 serum for one test, and takes 1 to 2 hours. Due to the lack of a rapid, thorough, and comprehensive testing method for blood donated by blood donors, many people are infected with infectious diseases such as hepatitis, AIDS, and syphilis when receiving blood transfusions, which seriously affects the physical and mental health of blood recipients. And social stability.
- the colloidal gold immunodiafiltration method was developed on the basis of enzyme-linked immunosorbent assay (ELISA).
- ELISA enzyme-linked immunosorbent assay
- the conjugate that was originally applied was labeled with an enzyme, called an enzyme immunodiafiltration test.
- the diafiltration test with colloidal gold as a marker was also developed in the early 1990's, also known as the gold immunodiafiltration test (IGFA).
- the principle of the colloidal gold immunodiafiltration method is based on a nitrocellulose membrane as a carrier, using the filterability of the microporous membrane and the capillary action to make the reaction between the antigen and the antibody, washing on a special diafiltration device, and using liquid
- the method of percolating the membrane is done quickly.
- colloidal gold immunodiafiltration method can be applied to almost all aspects of immunological detection, but is mainly used to detect antigenic substances (such as antigens or antibodies in the diagnosis of infectious diseases) that are not present in normal body fluids, as well as very low and special Abnormally elevated substances (such as HCG, alpha fetus Protein, etc.).
- antigenic substances such as antigens or antibodies in the diagnosis of infectious diseases
- very low and special Abnormally elevated substances such as HCG, alpha fetus Protein, etc.
- the technical problem to be solved by the present invention is to detect multiple infectious diseases at the same time by using the principle of colloidal gold immunodiafiltration, and to provide a sensitive, accurate and rapid multi-purpose test reagent cartridge.
- the kit for simultaneous detection of multiple infectious diseases disclosed by the present invention is composed of an immunodiafiltration gold standard method and a combined detection reaction device, a buffer solution, and a colloidal gold mark mixture solution;
- the nitrocellulose membrane in the immunodiafiltration gold standard joint detection reaction device described above is made of HBsAg monoclonal antibody (rat anti-human), HCV antigen, syphilis antigen, HIV antigen and four kinds of proteins and quality control at a certain distance.
- Goat anti-mouse IgG antibody, the spotting amount of the antigen is 0.3-3 ⁇ ⁇ ;
- the colloidal gold marker mixed solution is a mixed solution of four colloidal gold markers, including colloidal gold markers of HBsAg monoclonal antibody (rat anti-human), HCV antigen, syphilis antigen and HIV antigen; HBsAg monoclonal antibody ( Mouse anti-human) Colloidal gold-labeled protein concentration is 20-50 ⁇ g / ml, HCV antigen is labeled with colloidal gold label, protein concentration is 90-120 g / ml, syphilis antigen-labeled protein concentration It is 90-120 g / ml, and the protein concentration of the HIV antigen by colloidal gold oak is 80-120 g / ml. They are sequentially phased by a volume ratio of 1: 1: 1.2-2.5: 1.2-2.5. Mixed; colloidal gold particle size of 0-30nm;
- the buffer solution described therein is a PBS (buffer made from potassium dihydrogen phosphate or sodium dihydrogen phosphate and disodium hydrogen phosphate) containing 0.03-0.05% Tween 20 at pH 7.2-8.8. Buffer solution °
- the syphilis antigen described in the present invention may be a single syphilis antigen or a mixture of multiple syphilis antigens; the HIV antigen may be an HIV-1 (type 1 HIV) antigen, an HIV-2 (type 2 HIV) antigen, or Mixture of HIV-1 antigen and HIV-2 antigen.
- Another technical problem to be solved by the present invention is to provide a method for preparing the above-mentioned detection kit.
- the method for preparing a kit for simultaneously detecting multiple infectious diseases disclosed in the present invention includes the following steps:
- the HBsAg monoclonal antibody (rat anti-human) was placed in 0.02M PBS, pH 8.0 and dialyzed at 4 ° C overnight. After dialysis, the mouse anti-human HBsAg monoclonal antibody was diluted to 0.2-2. Omg / ml with 0.02M, ⁇ . ⁇ PBS, and stored at 4 ° C for future use.
- the HCV antigen was placed in 0.02M FBS pH 8.0 and dialyzed at 4 ° C overnight.
- the HCV antigen after dialysis was diluted to 0.2-2. Omg / ml with 0.02M, PBS pH 8.0, and stored at 4 ° C until use.
- the syphilis antigen was placed in 0.02M PBS, pH 8.0, and dialyzed at 4 ° C overnight. After dialysis, the syphilis antigen was diluted to 0.2-2. Omg / ml with 0.02M, pH8.0 PBS, and stored at 4 ° C for future use.
- the HIV antigen was placed in 0.02M PBS, pH 8.0, and dialyzed at 4 ° C overnight. After the dialysis, the HIV antigen was diluted to 0.2-2. Omg / ml with 0.02M, PBS pH8.0, and stored at 4 ° C for future use.
- the goat anti-mouse IgG antibody was placed in 0.02M, 8.0 pH PBS and dialyzed at 4 ° C overnight. After dialysis, the goat anti-mouse IgG antibody was diluted to 0.2-2. Omg / ml with 0.02M, PBS pH 8.0, and stored at 4 ° C for future use. -
- HBsAg monoclonal antibodies rat anti-human
- HCV antigen HCV antigen
- syphilis antigen HIV antigen
- NC nitrocellulose membrane
- the blocking solution is 0.05M pH7.2-8.0 PBS buffer containing 0.01-0.03% Tween20; the washing solution is 0.01M pH7.2-8.0 PBS buffer containing 0.03-0.05% Tween20. liquid.
- the colloidal gold markers of each syphilis antigen must be prepared separately, mixed, and stored for future use.
- the colloidal gold labeling of each HIV antigen must be prepared separately, mixed, and stored for future use.
- Tween20 was added to PBS at pH 7.2-8.8, so that the concentration of Tween20 was 0.03-0.05%.
- Another technical problem to be solved by the present invention is to disclose the application of the above detection kit in the simultaneous detection of hepatitis B, hepatitis C, syphilis, and AIDS infectious diseases.
- the detection method of the kit according to the present invention is as follows:
- HBsAg monoclonal antibody contained in colloidal gold labeling solution can react with goat anti-mouse IgG antibody, corresponding to goat anti-mouse IgG
- the position of the antibody will be colored, and it will be recognized by the naked eye.
- the kit cannot perform the detection experiment due to the quality of a component, the position on the membrane corresponding to the goat anti-mouse IgG antibody will not develop color, so Goat anti-mouse IgG antibodies allow quality control of the kit.
- the detection kit of the present invention uses the principle of colloidal gold immunodiafiltration, so that the relevant antigens and antibodies of various infectious diseases are reacted and washed on the same diafiltration device (nitrocellulose membrane), and the spots are visually observed Color development, for a variety of infectious diseases Detection.
- the kit of the invention has the advantages that:
- Multiple antibodies can be detected in the same device, and multiple antigens can be detected at the same time, achieving integration of multiple protein detection conditions.
- the kit of the present invention has the following advantages:
- Multiple antibodies can be detected in the same device, and multiple antigens can be detected at the same time, achieving integration of multiple protein detection conditions.
- the entire experiment can be completed in 3-5 minutes, which is suitable for large-scale rapid blood tests.
- This reagent kit has only two detection steps, that is, the sample addition and reaction are completed by diafiltration. The detection process takes only a few minutes, but the sensitivity is similar to that of an ELISA experiment that takes 1-2 hours to complete.
- the required serum volume is only 50ul, and only finger blood and ear blood can be collected.
- the ELISA method requires 100 ul of serum for one indicator, and about 400 ul of serum for four indicators. Therefore, this kit is very convenient for children and newborns, while ELISA sampling can only take veins, which is very painful for newborns.
- test result is not affected by the device only; it is not affected by the reaction environment.
- Color can be developed by adding colloidal gold marker, the operation steps are simple, and the reagent can be stored at room temperature for a long time.
- the kit of the present invention uses the principle of the colloidal gold immunodiafiltration method, and is implemented on the same carrier. Simultaneous detection of multiple antigens and antibodies is simple, fast, and accurate. It is applicable to the detection of multiple diseases of various blood samples, and is particularly suitable for large-scale blood tests. It also provides new ideas for the detection of infectious diseases. Brief description of the drawings
- Figure 1 is a schematic diagram of spotting on a nitrocellulose membrane
- Figure 2 is a schematic diagram showing the detection of serum No. 1 and the test results are all negative;
- Figure 3 is a schematic diagram showing the detection of serum No. 2; the test result is positive for hepatitis B virus surface antigen;
- Figure 4 is a schematic diagram showing the detection of serum No. 3; the test results are syphilis antibodies, and HIV-1 & 2 antibodies are positive;
- Figure 5 is a schematic diagram showing the detection of serum No. 4; the test results are positive for syphilis antibodies, AIDS HIV-1 & 2 antibodies, and hepatitis C virus antibodies;
- C-C indicates that the horizontal line of goat anti-mouse IgG antibody is positive.
- the kit uses antibodies and materials
- HBsAg monoclonal antibody (rat anti-human) Sl
- HBsAg monoclonal antibody (rat anti-human) S2
- Beile Biotechnology Co., Ltd HCV antigen, TP47 syphilis antigen, TP15 syphilis antigen, TP47 / TP15 syphilis mixed antigen, HIV-1 antigen, HIV-2 antigen, HIV-1 / 2 mixed antigen were provided by American BioDesign Company
- nitrocellulose membrane was provided by S & S company
- the tested serum was provided by Shanghai Centers for Disease Control.
- the preparation method of the immunodiafiltration gold standard combined detection reaction device is as follows:
- HBsAg monoclonal antibody mouse anti-human
- P H8 .0 in PBS 4 ° C
- Dialyzed mouse anti-human HBsAg mAb S2 was treated with 0.02M, ⁇ . ⁇ PBS Diluted to 0.5m g / ml, 4 ° C for use.
- HCV antigen Place the HCV antigen in 0.02M FBS, pH 8.0, and dialyze at 4 ° C overnight. After dialysis, the HCV antigen was diluted to 0.4 mg / ml with 0.02M FBS pH 8.0, and stored at 4 ° C until use. '
- HIV-1 / 2 mixed antigen put HIV-1 / 2 mixed antigen in 0.02M, ⁇ . ⁇ FBS, and dialyze at 4 ° C overnight.
- the HIV-1 / 2 mixed antigen after dialysis was diluted to 0.6 mg / ml with 0.02M, ⁇ . ⁇ PBS, and stored at 4 ° C until use.
- Sheep anti-mouse IgG antibody was placed in 0.02M, pH8.0 PBS, and dialyzed at 4 ° C overnight. HIV-1/2 mixed antigen after dialysis with 0.02M, pH8.0 in PBS were diluted to 0. 6 mg / ml, 4 ° C for use.
- the buffer solution is a solution made up of a volume of PBS, pH 7.8, 0.10M and 0.30% Tween20.
- Colloidal gold labeling solution consists of HBsAg monoclonal antibody (rat anti-human) S1 colloidal gold label, HCV antigen colloidal gold label, TP47 / TP15 syphilis mixed antigen colloidal gold label,
- the colloidal gold mark of HIV-1 / 2 mixed antigen is mixed in a volume ratio of 1: 1: 1.2-2.5: 1.2-2.5.
- the particle size of the colloidal gold used for each colloidal gold marker was 30 nm.
- the colloidal gold label is prepared as follows:
- the preparation method of colloidal gold maggots of TP15 antigen is the same as TP47.
- the colloidal gold label of HIV-2 antigen is prepared in the same way as HIV-1.
- the colloidal gold labeling of each HIV antigen should be prepared separately, and then diluted, mixed and stored for a certain multiple.
- the kit was used to test different sera.
- the information provided by the hospital showed that the provider of serum No. 1 did not suffer from any of the four infectious diseases mentioned above; the provider of serum No. 2 only had hepatitis C; No. 3
- the provider of the serum had AIDS and syphilis; the provider of serum No. 4 had hepatitis B and syphilis.
- the test results are shown in Figure 2, Figure 3, Figure 4, Figure 5, and Figure 5.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003521370A JP3853317B2 (ja) | 2001-08-17 | 2001-10-30 | 複数感染症の同時検出診断キットおよびその製造方法 |
DE60109311T DE60109311T2 (de) | 2001-08-17 | 2001-10-30 | Kit zur simultanen diagnose mehrerer ansteckender krankheiten und verfahren zu seiner herstellung |
EP01274437A EP1327885B1 (en) | 2001-08-17 | 2001-10-30 | A kit for the simultaneous diagnosis of a plurality of infectious diseases and a method for preparation of it |
CA002422942A CA2422942A1 (en) | 2001-08-17 | 2001-10-30 | Diagnostic kit for simultaneously detecting multiple infectious disease s and the preparation thereof |
US10/393,555 US20030165970A1 (en) | 2001-08-17 | 2003-03-21 | Diagnostic kit for simultaneously detecting multiple infectious diseases and the preparation thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB011265000A CN1164949C (zh) | 2001-08-17 | 2001-08-17 | 用于同时检测多种传染性疾病的试剂盒及其制备方法 |
CN01126500.0 | 2001-08-17 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/393,555 Continuation US20030165970A1 (en) | 2001-08-17 | 2003-03-21 | Diagnostic kit for simultaneously detecting multiple infectious diseases and the preparation thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003016914A1 true WO2003016914A1 (fr) | 2003-02-27 |
Family
ID=4666516
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2001/001519 WO2003016914A1 (fr) | 2001-08-17 | 2001-10-30 | Kit de diagnostic simultane d'une pluralite de maladies infectieuses et technique de preparation de celui-ci |
Country Status (7)
Country | Link |
---|---|
US (1) | US20030165970A1 (zh) |
EP (1) | EP1327885B1 (zh) |
JP (1) | JP3853317B2 (zh) |
CN (1) | CN1164949C (zh) |
CA (1) | CA2422942A1 (zh) |
DE (1) | DE60109311T2 (zh) |
WO (1) | WO2003016914A1 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100396774C (zh) * | 2006-07-17 | 2008-06-25 | 华中农业大学 | 检测磺胺类药物残留的免疫胶体金试纸条 |
CN115015543A (zh) * | 2022-04-17 | 2022-09-06 | 吉林迅准生物技术有限公司 | 一种多项病原体联合检测装置及其制备方法 |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050153382A1 (en) * | 2002-06-06 | 2005-07-14 | Chengdu Kuachang Science And Technology Co., Ltd. | Biochip kit comprising biochip based on antigen-antibody reactions, and its usage |
CN1164948C (zh) * | 2002-06-06 | 2004-09-01 | 成都夸常科技有限公司 | 一种基于抗原抗体反应的试剂盒 |
CN100434901C (zh) * | 2006-01-12 | 2008-11-19 | 上海交通大学 | 血红蛋白凝胶层析的教学试剂盒 |
CN101558309B (zh) | 2006-09-28 | 2014-02-26 | 麦克法兰布奈特医疗研究与公共健康研究所有限公司 | 一种诊断方法和用于此的试剂盒 |
CA2578313A1 (en) * | 2007-03-01 | 2007-05-14 | Biolytical Laboratories Inc. | Highly accurate rapid parallel immunoassay device |
CN101487062B (zh) * | 2008-10-31 | 2013-11-27 | 武汉大学 | 同步检测肝炎、艾滋病毒和梅毒螺旋体核酸的试剂盒 |
GB201018096D0 (en) * | 2010-10-27 | 2010-12-08 | Binding Site Group The Ltd | Coated beads |
CN102323401B (zh) * | 2011-05-30 | 2014-04-16 | 上海北加生化试剂有限公司 | 葡萄糖-6-磷酸异构酶抗原体外检测试剂盒及制备方法 |
RU2488832C1 (ru) * | 2012-01-13 | 2013-07-27 | Общество с ограниченной ответственностью "Передовые диагностические платформы" | Способ комплексной диагностики инфекционных заболеваний человека путем твердофазного иммуноферментного анализа |
CN102980997B (zh) * | 2012-06-23 | 2014-11-05 | 北京新兴四寰生物技术有限公司 | EB病毒衣壳抗原IgM抗体胶体金法检测试剂及其制备方法 |
CN102768277B (zh) * | 2012-07-25 | 2014-05-07 | 成都协和生物技术有限责任公司 | 口腔黏膜渗出液胶体金法检测hiv抗体的样本稀释液及其制备方法 |
CN103175958B (zh) * | 2013-02-17 | 2015-04-08 | 北京市药品检验所 | 快速鉴别重组乙型肝炎疫苗的方法 |
CN103792351A (zh) * | 2014-01-23 | 2014-05-14 | 新疆纳秒脉冲技术应用研究所 | 一种快速检测革兰氏菌的方法及试剂盒 |
US10416158B2 (en) | 2014-03-11 | 2019-09-17 | Wisconsin Alumni Research Foundation | Peptide MHCII tetramers to detect endogenous calnexin specific CD4 T cells |
WO2016035099A1 (en) * | 2014-09-05 | 2016-03-10 | Meril Diagnostics Private Limited | A flow through device for detection of multiple bioanalytes and a process thereof |
CN105486854B (zh) * | 2015-09-29 | 2017-12-05 | 南方医科大学 | 一种信号放大方法及相关装置 |
CN106290927B (zh) * | 2016-07-26 | 2018-12-14 | 鲁东大学 | 强力霉素快速检测试剂盒及其制备、使用方法 |
CN106771145A (zh) * | 2016-08-23 | 2017-05-31 | 广东优尼德生物科技有限公司 | 一种检测d‑二聚体斑点金渗滤试剂盒及定量检测方法 |
CN106771144A (zh) * | 2016-08-23 | 2017-05-31 | 广东优尼德生物科技有限公司 | 一种检测c‑反应蛋白斑点免疫金渗滤试剂盒及定量检测方法 |
CN108761058A (zh) * | 2018-05-19 | 2018-11-06 | 大连大学 | 用于平行检测多种感染性疾病标志物的纸芯片及方法 |
CN109900896A (zh) * | 2019-03-12 | 2019-06-18 | 江苏伯纳德生物科技发展有限公司 | 一种酶联免疫法检测试剂盒及其制备方法 |
CN109991416A (zh) * | 2019-03-12 | 2019-07-09 | 江苏伯纳德生物科技发展有限公司 | 一种免疫层析法检测试剂盒及其制备方法 |
CN110078822B (zh) * | 2019-05-20 | 2021-03-02 | 浙江大学医学院附属第一医院 | 抗梅毒螺旋体膜蛋白Tp47的单克隆抗体ZJTP47-1B3及其应用 |
CN110907638B (zh) * | 2020-02-14 | 2020-09-22 | 北京纳百生物科技有限公司 | 一种免疫胶体金均相标记用抗体分散剂及其应用 |
US11549114B2 (en) * | 2020-03-27 | 2023-01-10 | Apollo Biomedical, LLC | Multiple rapid detection kits and methods for various viruses |
US11011278B1 (en) * | 2020-09-21 | 2021-05-18 | Biolytical Laboratories Inc. | Methods and rapid test kits facilitating epidemiological surveillance |
CN112684171B (zh) * | 2021-01-20 | 2022-09-30 | 季华实验室 | 一种梅毒抗体检测的免疫传感载体、试剂盒和制备方法 |
CN117571988A (zh) * | 2024-01-09 | 2024-02-20 | 山东康华生物医疗科技股份有限公司 | 一种血筛多线试纸条、试剂盒及其制备方法和应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1140258A (zh) * | 1995-07-05 | 1997-01-15 | 中国人民解放军第四军医大学 | 检测乙型肝炎病毒抗体的免疫胶体金试剂及方法 |
US5637508A (en) * | 1993-03-26 | 1997-06-10 | Geo-Centers, Inc. | Biomolecules bound to polymer or copolymer coated catalytic inorganic particles, immunoassays using the same and kits containing the same |
JP2000097942A (ja) * | 1998-09-18 | 2000-04-07 | Matsushita Electric Ind Co Ltd | 免疫クロマトグラフィーのためのキット |
CN1307238A (zh) * | 2000-02-02 | 2001-08-08 | 昆明广博科技有限公司 | 多种常见性病快速检测试纸条及其制备方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW203120B (zh) * | 1985-10-04 | 1993-04-01 | Abbott Lab | |
EP0302154A1 (en) * | 1987-07-20 | 1989-02-08 | Soficorp Scientific Inc. | Detection of HIV and anti-lymphocyte antibodies |
GB8915512D0 (en) * | 1989-07-06 | 1989-08-23 | Sec Dep For Health | Silver enhanced gold-labelled immuno assay method |
US5474900A (en) * | 1990-03-16 | 1995-12-12 | Sekisui Chemical Co., Ltd. | Process for preparing purified syphilis antigen from Treponema palljdum |
WO1992017782A1 (en) * | 1991-03-28 | 1992-10-15 | Meiji Seika Kabushiki Kaisha | Simple analyzing device |
DE29811606U1 (de) * | 1998-06-29 | 1999-05-06 | Sension, biologische Detektions- und Schnelltestsysteme GmbH, 86167 Augsburg | Kombi-Vorrichtung zur simultanen Durchführung von Immunfiltrationstests |
-
2001
- 2001-08-17 CN CNB011265000A patent/CN1164949C/zh not_active Expired - Fee Related
- 2001-10-30 DE DE60109311T patent/DE60109311T2/de not_active Expired - Fee Related
- 2001-10-30 WO PCT/CN2001/001519 patent/WO2003016914A1/zh active IP Right Grant
- 2001-10-30 CA CA002422942A patent/CA2422942A1/en not_active Abandoned
- 2001-10-30 EP EP01274437A patent/EP1327885B1/en not_active Expired - Lifetime
- 2001-10-30 JP JP2003521370A patent/JP3853317B2/ja not_active Expired - Fee Related
-
2003
- 2003-03-21 US US10/393,555 patent/US20030165970A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5637508A (en) * | 1993-03-26 | 1997-06-10 | Geo-Centers, Inc. | Biomolecules bound to polymer or copolymer coated catalytic inorganic particles, immunoassays using the same and kits containing the same |
CN1140258A (zh) * | 1995-07-05 | 1997-01-15 | 中国人民解放军第四军医大学 | 检测乙型肝炎病毒抗体的免疫胶体金试剂及方法 |
JP2000097942A (ja) * | 1998-09-18 | 2000-04-07 | Matsushita Electric Ind Co Ltd | 免疫クロマトグラフィーのためのキット |
CN1307238A (zh) * | 2000-02-02 | 2001-08-08 | 昆明广博科技有限公司 | 多种常见性病快速检测试纸条及其制备方法 |
Non-Patent Citations (1)
Title |
---|
See also references of EP1327885A4 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100396774C (zh) * | 2006-07-17 | 2008-06-25 | 华中农业大学 | 检测磺胺类药物残留的免疫胶体金试纸条 |
CN115015543A (zh) * | 2022-04-17 | 2022-09-06 | 吉林迅准生物技术有限公司 | 一种多项病原体联合检测装置及其制备方法 |
CN115015543B (zh) * | 2022-04-17 | 2023-02-28 | 吉林迅准生物技术有限公司 | 一种多项病原体联合检测装置及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
EP1327885B1 (en) | 2005-03-09 |
CN1405564A (zh) | 2003-03-26 |
DE60109311T2 (de) | 2006-04-06 |
DE60109311D1 (de) | 2005-04-14 |
EP1327885A1 (en) | 2003-07-16 |
US20030165970A1 (en) | 2003-09-04 |
CN1164949C (zh) | 2004-09-01 |
EP1327885A4 (en) | 2004-04-21 |
CA2422942A1 (en) | 2003-03-19 |
JP3853317B2 (ja) | 2006-12-06 |
JP2004538489A (ja) | 2004-12-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2003016914A1 (fr) | Kit de diagnostic simultane d'une pluralite de maladies infectieuses et technique de preparation de celui-ci | |
Arai et al. | Evaluation of a rapid immunochromatographic test for detection of antibodies to human immunodeficiency virus | |
Widell et al. | Detection of hepatitis C core antigen in serum or plasma as a marker of hepatitis C viraemia in the serological window‐phase | |
Sickinger et al. | Multicenter evaluation of a new, automated enzyme-linked immunoassay for detection of human immunodeficiency virus-specific antibodies and antigen | |
EP1933142B1 (en) | Rapid immunochromatographic detection by amplification of the colloidal gold signal | |
Gasasira et al. | False-positive results of enzyme immunoassays for human immunodeficiency virus in patients with uncomplicated malaria | |
Martínez et al. | Human immunodeficiency virus antibody testing by enzyme-linked fluorescent and western blot assays using serum, gingival-crevicular transudate, and urine samples | |
Schramm et al. | A simple saliva-based test for detecting antibodies to human immunodeficiency virus | |
EP1933147B1 (en) | Rapid immunochromatographic detection by amplification of the colloidal gold signal | |
WO2003023403A1 (en) | A KIT FOR THE SIMULTANEOUS DIAGNOSIS OF FOUR KINDS OF DISEASES (ToRCH) RESULTING IN DEFORMITY FETUS AND A METHOD FOR PREPARATION OF IT | |
CN1409111A (zh) | 一种能同时检测多种与疾病有关的抗原、抗体的装置 | |
KR20100063089A (ko) | 생리 액, 자궁내막/생리 세포, 양수, 제대혈 또는 기타 시료의 감염성 질환 검사 | |
EP1933143B1 (en) | Rapid immunochromatographic detection by amplification of the colloidal gold signal | |
US20240142446A1 (en) | Test kits, devices and methods for detecting hiv infection | |
Khan et al. | FREQUENCY OF HEPATITIS B AND C POSITIVE CASES AMONG BLOOD DONORS VISITING BLOOD TRANSFUSION CENTRES OF DISTRICT ABBOTTABAD | |
Yadav et al. | Seropositivity of hepatitis B viral infection among liver disorder patients, voluntary blood donors and hospital personnel | |
Mohammed | Serodetection of HBV, HCV, HIV and Treponema pallidum among Blood Donors in Almak Nimir University Hospital, Shendi, Sudan | |
WO2002050544A1 (en) | Multiple target test useful for pre-donation screening of blood | |
Hassen et al. | Evaluating Serum Urea, Creatinine and Hemoglobin Level in Chronic Renal Failure of Pre and Post Dialysis at St. Paul’s Hospital Millennium Medical College, Addis Ababa, Ethiopia | |
Taheu et al. | Hepatitis B and C Virus, Human Immunodeficiency Virus Co-infection among Pregnant Women in Semi-rural Health District, Cameroon | |
Abdullah et al. | Detection and Identification of Hepatitis B, C and HIV viruses in Benghazi city | |
SERUM et al. | RAPID HBSAG/HIV I&II/HCV/SYPHILIS PANEL TEST | |
Hanan | Detection and Identification of Hepatitis B, C and HIV viruses in Benghazi city | |
BLOOD | Rapid HIV I&II/HCV Panel Test Card | |
Olaniyan | Comparative study of the frequency of occurrence of HBeAg, anti-HBe, anti-HIV and anti-HCV in pre-icteric, icteric and post-icteric HBsAg seropositive patients |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ PH PL PT RO SD SE SG SI SK SL TJ TM TR TT TZ UG US UZ VN YU ZA Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZW AM AZ BY KG KZ MD TJ TM AT BE CH CY DE DK ES FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW MR NE SN TD TG US Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001274437 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10393555 Country of ref document: US |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003521370 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2422942 Country of ref document: CA |
|
WWP | Wipo information: published in national office |
Ref document number: 2001274437 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 2001274437 Country of ref document: EP |